SCHEMBL23792017

SCHEMBL23792017

CC(C)Cc1sc(NCC(NC(=O)c2cccs2)C(=O)O)nc1-c1ccc(Cl)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ MAPT P10636 3/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ GRN P28799 1/20 0.40
▸ SORT1 Q99523 1/20 0.40
▸ LMNA P02545 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ PKM P14618 1/20 0.40
▸ HSPA5 P11021 2/20 0.39
▸ HSPA2 P54652 1/20 0.39
▸ POLB P06746 3/20 0.39
▸ GAA P10253 1/20 0.39
▸ ITGAL P20701 7/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ ITGB2 P05107 6/20 0.37
▸ ICAM1 P05362 6/20 0.37
▸ CTSB P07858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23782529 0.89 GRN (0.47) MEN1KMT2AGRNSORT1LMNA
SCHEMBL30173796 0.89 GRN (0.47) MEN1KMT2AGRNSORT1LMNA
SCHEMBL23792013 0.87 GRN (0.41) MEN1KMT2AGRNSORT1LMNA
SCHEMBL26240299 0.87 GRN (0.40) MEN1KMT2AALDH1A1GRNSORT1
SCHEMBL23792015 0.86 GRN (0.40) MEN1KMT2AMAPTGRNSORT1
SCHEMBL23792000 0.84 FPR2 (0.45) MEN1KMT2AMAPTNPSR1ALDH1A1
SCHEMBL23792010 0.84 GRN (0.45) MEN1KMT2AALDH1A1GRNSORT1
SCHEMBL23792019 0.83 GRN (0.38) GRNSORT1LMNARAB9APOLB
SCHEMBL23791724 0.83 DHODH (0.42) MAPTNPSR1ALDH1A1GRNSORT1
SCHEMBL23782338 0.82 ACE (0.37) GRNSORT1LMNARAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
WO-2021178488-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-09-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 MEN1 2104/4885KMT2A 1931/4885MAPT 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback